# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours par raspansa	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response		*								5 D 1	1.	- CD	D (	4 - T	
1. Name and Address of Reporting Person * Bell John K			2. Issuer Name and Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
(Last) (First) (Middle) C/O DELMAR PHARMACEUTICALS, INC., SUITE 720-999 WEST BROADWAY			(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/08/2018					XDire		e title below)		Owner er (specify below	)		
(Street)  VANCOUVER, A1 V5Z 1K5			2	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person					e)	
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of S (Instr. 3)	Title of Security 2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)  3. Tran Code (Instr. 8		8) (1	(A) or Disposed of (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			ed 0	Ownership o	eneficial wnership			
						s, warra	ants,	ired, Dispo	isplays a cu osed of, or Be nvertible sec	neficiall urities)	y Owned	l				
1. Title of Derivative Security (Instr. 3)	Conversion	Date (Month/Day/Year)	3A. Deemed Execution Date, if	if Transaction Code I (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date (Month/Day/Year)		Amou Under Secur	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form of Derivativ Security: Direct (D or Indirect	
				Code	V	(A)	(D)	Date Exercisabl	Expiration e Date	Title	or Nu of	mount imber ares				
Options								<u>(1)</u>	11/08/202	Com	mon 40	.000	\$ 0	40,000		

#### **Reporting Owners**

B C N (AU	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Bell John K C/O DELMAR PHARMACEUTICALS, INC. SUITE 720-999 WEST BROADWAY VANCOUVER, AI V5Z 1K5	X						

## **Signatures**

/s/ Anthony Scott Praill, attorney-in-fact for John K. Bell	11/13/2018
Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to the option vest in twelve (12) equal monthly installments beginning on December 8, 2018.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.